Mechanism
Synthetic pentadecapeptide from a gastric protein; preclinically reported to drive angiogenesis and tissue repair. Human efficacy unproven.
Dosing
Daily subcutaneous or intramuscular injection, ~300-500 mcg/day in standard use; advanced schedules dose 2x daily.
Reconstitution
3 mL bacteriostatic water gives ~3,333 mcg/mL (gradual); 2 mL gives ~5,000 mcg/mL (advanced).
Storage
Freeze the lyophilized vial; refrigerate the reconstituted solution and use within ~30 days.
Quick answerAcross documented research protocols, the 10 mg BPC-157 vial is commonly reconstituted with 3 mL of bacteriostatic water, with the research literature referencing approximately 300 mcg per dose measured from that solution. These numbers characterize reported research handling and are shared solely for research-use-only, non-clinical purposes.
Reconstitution calculator
Mix & measure BPC-157 · 10 mg
Pre-filled with this protocol’s recommended BAC water and documented starting dose — edit any field to run your own numbers.
Vial strengthmgBAC watermLYour dose
Concentration—mg/mL
Draw volume—mL
On the syringe—units
Doses / vial—
Reconstitution math only — not dosing advice. U-100 syringe: 100 units = 1 mL. Full reconstitution guide → · Advanced calculator →
Dosing & Reconstitution Guide
Two reconstitution strategies with accurate daily dosing, step by step
Standard / Gradual Approach (3 mL = ~3,333 mcg/mL)
▪
Reconstitute: Add 3.0 mL bacteriostatic water to one 10 mg vial → final concentration: ~3,333 mcg/mL.
▪
Typical daily range: 300–500 mcg once daily across a 4–8 week course.
▪
Easy measuring: At ~3,333 mcg/mL, 300 mcg ≈ 9 units and 500 mcg ≈ 15 units on a U-100 insulin syringe. Note 9 units is just under 10 — a smaller-graduation syringe helps precision.
Phase / Week(s) Daily Dose Volume (U-100 units / mL) Weeks 1–4 300 mcg (1× daily) ~9 units (0.09 mL) Weeks 5–8 500 mcg (1× daily) ~15 units (0.15 mL)
Advanced / Aggressive Approach (2 mL = ~5,000 mcg/mL)
▪
Reconstitute: Add 2.0 mL bacteriostatic water to one 10 mg vial → final concentration: ~5,000 mcg/mL.
▪
Typical daily range: 500–750 mcg per injection, 2× daily for those referencing higher BPC-157 schedules.
▪
Easy measuring: At ~5,000 mcg/mL, 500 mcg ≈ 10 units and 750 mcg ≈ 15 units per injection on a U-100 syringe.
▪
Note: Each injection volume stays well within a single 100-unit insulin syringe.
Phase / Week(s) Daily Dose Volume (U-100 units / mL) Weeks 1–4 500 mcg (2× daily) ~10 units (0.10 mL) per injection Weeks 5–8 750 mcg (2× daily) ~15 units (0.15 mL) per injection
Higher concentration: mixing to ~5,000 mcg/mL keeps injection volumes small even when dosing 500–750 mcg twice daily. Splitting the total across two injections is common in higher-dose reference schedules.
Ask what generic AI won't
ChatGPT dodges your BPC-157 dosing questions. OpenPeptide answers them.
Documented protocols, exact reconstitution math, and real sources — no lectures, no dead ends.
Why researchers study it
Why BPC-157 draws research interest
These are the directions researchers and the peptide community most often explore BPC-157 for — so you know you’re in the right place. They describe what is being studied, not proven benefits, approved uses, or promised results.
Tissue repair
Studied preclinically as a pentadecapeptide involved in tissue repair, with animal research exploring wound-healing and cellular recovery pathways.
Injury recovery
Investigated in animal studies on recovery from soft-tissue injury, including tendon, ligament, and muscle models; remains investigational, not approved.
Gut/GI protection
Explored in preclinical research on protection of the gastrointestinal tract, reflecting its origin in a protein found in gastric juice.
Anti-inflammatory
Researched as an anti-inflammatory agent in animal-only studies; not FDA-approved and used only in a research context.
Evidence ranges from early laboratory work to clinical trials depending on the use — the sections below cover the actual data and sources.
01 · Dosing & reconstitution
Frequency: one subcutaneous (or intramuscular) injection each day. A moderate 300–500 mcg daily dose is the most commonly referenced range for tissue-repair protocols[3]. These figures come from reference protocols, not from approved human dosing.
i
Important: Read the Prep & Injection Guide first — it covers the preparation and safety basics that every protocol on this site assumes.
Reconstitution Steps
1
Draw the chosen volume of bacteriostatic water (3.0 mL for ~3,333 mcg/mL, or 2.0 mL for ~5,000 mcg/mL) into a sterile syringe.
2
Release it slowly against the vial’s inner wall to reduce foaming.
3
Swirl or roll gently until fully dissolved — don’t shake hard.
4
Note the mixing date and store at 2–8 °C (35.6–46.4 °F), shielded from light.
02 · What you’ll need
Supplies Needed
Quantities below assume a 4–8 week course of daily injections at a moderate dose.
✓Peptide Vials (BPC-157, 10 mg each)
A single 10 mg vial covers the early weeks of a moderate daily protocol; higher or twice-daily dosing uses more.
4 weeks (300–500 mcg/day): ~1–2 vials 8 weeks (300–500 mcg/day): ~2–3 vials Advanced (500–750 mcg, 2×/day): more vials needed
✓Insulin Syringes (U-100, 1 mL)
Per injection: 1 syringe 8 weeks (once daily): ~56 syringes 8 weeks (twice daily): ~112 syringes
✓Bacteriostatic Water (10 mL bottles)
Use 3.0 mL (gradual) or 2.0 mL (advanced) per 10 mg vial for reconstitution.
4 weeks (1–2 vials): 3–6 mL → 1 bottle 8 weeks (2–3 vials): 6–9 mL → 1 × 30 mL bottle
✓Alcohol Swabs
One for the vial stopper + one for the injection site each time.
Per injection: 2 swabs 8 weeks (once daily): ~112 swabs → 1–2 boxes
Dosing Protocol
A suggested daily injection approach based on common reference doses.
▪Start: Begin around 300 mcg per day to gauge tolerability, then adjust as needed. ▪Frequency: 1–2 injections per day; advanced schedules raise frequency rather than single-dose size. ▪Cycle Length: Typically 4–8 weeks; some references extend to ~12 weeks.
Storage Instructions
Correct storage is what preserves the peptide’s stability and potency.
▪Lyophilized: Hold the dry vial frozen at −20 °C (−4 °F) until mixing; shield from moisture and light[11]. ▪Reconstituted: Chill at 2–8 °C (35.6–46.4 °F) as soon as it’s mixed and use within ~30 days[11]. ▪Handling: Let frozen vials warm to room temperature before opening so condensation won’t form; keep the solution clear of heat and direct light. ▪Freeze–thaw: Avoid repeated freeze–thaw cycles, which degrade the peptide[12].
03 · Good to know
Important Notes
Practical points that keep daily administration safe and consistent.
▪Daily consistency: Space injections evenly and keep to a steady schedule for the whole protocol. ▪Sterile technique: Use a fresh sterile U-100 insulin syringe each time and drop it straight into a puncture-proof sharps container afterward[14]. ▪Site rotation: Move injection sites (abdomen, thighs, upper arms), keeping each at least 1 inch from the last to limit irritation[15]. ▪Higher-frequency dosing: For advanced schedules, split the daily total across two or more injections rather than one large volume. ▪Side-effect monitoring: Watch for injection-site discomfort, headache or nausea; consult a professional if concerns arise, and consider cycling off after ~8 weeks.
04 · How it works
How This Works
BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide — a 15-amino-acid sequence derived from a protein found in gastric juice[3]. Nearly all of the evidence behind it comes from animal and in-vitro (preclinical) studies, not from completed human efficacy trials.
In those preclinical models it has been reported to promote angiogenesis — the growth of new blood vessels — through the VEGFR2–Akt–eNOS / nitric-oxide pathway, which may help explain its observed effects on healing[1][4].
Animal research has also described accelerated repair of tendon, ligament, muscle, bone and gut tissue, alongside cytoprotective and anti-inflammatory activity — particularly protection of the gastrointestinal lining[2][4].
Important caveat: human efficacy is unproven. The evidence base is overwhelmingly preclinical, and there are no completed, published Phase 2 or 3 human efficacy trials — only early-stage safety work[9]. Reported mechanisms should be read as hypotheses from laboratory and animal data.
BPC-157 is not an approved medicine. It is an unapproved research chemical presented here for research and educational purposes only and is not approved for general human use.
05 · Daily habits
Lifestyle Factors
Habits that may support recovery alongside the protocol.
▪Nutrition: Eat a balanced, protein-forward diet to give tissue repair the building blocks it needs. ▪Activity & rest: Combine appropriate movement with adequate rest so healing tissue can recover. ▪Hydration: Keep fluids up across the protocol. ▪Sleep & stress: Aim for solid sleep and manage stress, both of which support recovery.
06 · What to expect
Potential Benefits & Side Effects
What preclinical research and anecdotal reports describe; human evidence is limited and individual results vary.
Potential Benefits
▪Tissue repair (preclinical): Animal studies report faster tendon, ligament, muscle and bone healing[4]. ▪GI protection (preclinical): Reported cytoprotective effects on the gastrointestinal lining in animal models[2]. ▪Anti-inflammatory signalling: Preclinical anti-inflammatory and angiogenic activity has been described[1]. ▪Note on humans: These benefits are not established in humans — no completed Phase 2/3 efficacy trials exist.
Common Side Effects
▪Injection-site reactions: Discomfort, redness or soreness at the site can occur; rotating sites helps. ▪Other reported effects: Headache and nausea have been noted anecdotally. ▪Unknown long-term profile: Long-term human safety data is limited; caution and monitoring are advised.
07 · Injection technique
Injection Technique
Subcutaneous (or intramuscular) injection technique, following established clinical practice and CDC guidance[13][14].
Pre-Injection Preparation
▪Wash your hands well with soap and water[14]. ▪Wipe the vial stopper with an alcohol swab and let it air-dry. ▪Pick a site (abdomen, thigh, or upper arm) and wipe it with a fresh alcohol swab, letting it dry fully[13]. ▪Carefully draw the intended dose, then check for air bubbles and push any out.
Injection Procedure
▪Pinch about a 1-inch fold of skin between thumb and forefinger[15]. ▪Insert the needle into the pinch at a 45–90-degree angle (use 45 degrees if the fat layer is thin)[13][14]. ▪Skip aspiration for subcutaneous shots — it isn’t needed and can add discomfort[13]. ▪Press the plunger slowly and steadily until it’s fully down. ▪Pull the needle straight out and, if needed, press lightly with clean gauze.
Post-Injection Care
▪Drop the used syringe straight into a puncture-proof sharps container — never recap a needle[14]. ▪Put the reconstituted vial back in the fridge right away. ▪Rotate the site with each injection (at least 1 inch over) to prevent irritation[15]. ▪Watch the site for excess redness, swelling, or signs of infection.
08 · Where to source
Recommended Source
For high-purity research peptides, we point researchers to Prime Lab Peptides for BPC-157 (10 mg).
Why Prime Lab Peptides?
▪Top-rated on Trustpilot: Independently reviewed as the highest-rated peptide lab on Trustpilot — making it the best current source in the USA. ▪Third-party tested: Every batch ships with a Certificate of Analysis (COA) confirming purity and composition. ▪Consistent quality: ISO-aligned manufacturing and handling keep product integrity reliable batch to batch. ▪Cold-chain integrity: Temperature-controlled shipping and storage across the whole fulfilment chain. ▪Research-grade purity: Fit for educational and research use that demands high-quality peptides.
Note: Product availability and specifications subject to change. Verify current product details on supplier website.
Shop at Prime Lab Peptides →
09 · The evidence
References
1
Journal of Pharmacological Sciences
Klicek R et al. — BPC-157 modulates the NO-system and promotes healing (rat models of injury and fistula).
View Source ↗ 2
World Journal of Gastroenterology (PMC)
Sikiric P et al. — Pentadecapeptide BPC-157: from the GI tract to whole-body cytoprotection and healing.
View Source ↗ 3
Current Pharmaceutical Design (PMC)
Sikiric P et al. — Stable gastric pentadecapeptide BPC-157 in the treatment of wound healing and tissue repair.
View Source ↗ 4
Life Sciences
Seiwerth S et al. — BPC-157 and standard angiogenic growth factors: gastrointestinal tract healing and beyond.
View Source ↗ 5
Journal of Orthopaedic Research
Chang CH et al. — BPC-157 promotes tendon-to-bone healing in a rat rotator-cuff model.
View Source ↗ 6
HSS Journal (PubMed)
Vasireddi N et al. — Emerging use of BPC-157 in orthopaedic sports medicine: a systematic review (2025).
View Source ↗ 7
Pharmaceuticals (MDPI)
Józwiak M et al. — Multifunctionality and possible medical application of BPC-157: literature and patent review (2025).
View Source ↗ 8
ClinicalTrials.gov
NCT02637284 — PCO-02: Phase I safety and pharmacokinetics trial of oral BPC-157 (early-stage human study).
View Source ↗ 9
Journal of Dental Anesthesia and Pain Medicine
Review of BPC-157 pharmacology and reported regenerative effects.
View Source ↗ 10
PubMed Central (PMC)
BPC-157 collagen-regeneration and wound-healing efficacy data (preclinical).
View Source ↗ 11
GenScript
Peptide storage and handling guidelines (lyophilized and reconstituted peptides).
View Source ↗ 12
Bachem
Handling and storage guidelines for peptides (stability and freeze–thaw cycles).
View Source ↗ 13
Centers for Disease Control and Prevention (CDC)
Vaccine administration: subcutaneous injection technique, angle and site guidance (no aspiration).
View Source ↗ 14
WHO (NCBI Bookshelf)
Guideline on safety-engineered syringes and aseptic technique for IM, ID and SC injections (2016).
View Source ↗ 15
Pharmacologic Considerations of the Subcutaneous Route (PMC)
Subcutaneous injection technique and site rotation to prevent lipohypertrophy.
View Source ↗ 16
Prime Lab Peptides
BPC-157 (10 mg) product page — quality documentation and certificates of analysis.
View Source ↗